<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03018418</url>
  </required_header>
  <id_info>
    <org_study_id>UCCI-GI-16-01</org_study_id>
    <nct_id>NCT03018418</nct_id>
  </id_info>
  <brief_title>Proton Therapy in Reducing Toxicity in Anal Cancer</brief_title>
  <official_title>A Prospective Pilot Study to Evaluate the Feasibility of Intensity Modulated Proton Therapy in Reducing Toxicity in Anal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jordan Kharofa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether the amount of radiation given to
      the normal areas around the anal cancer can be reduced by using Proton Therapy while reducing
      the side effects that are seen with standard therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of acute toxicity</measure>
    <time_frame>3 months</time_frame>
    <description>Grade 3 or greater hematologic, gastrointestinal, genitourinary, and dermatologic toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of late toxicity</measure>
    <time_frame>every 6 months up to 60 months</time_frame>
    <description>Grade 3 or greater hematologic, gastrointestinal, genitourinary, and dermatologic toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>every 6 months up to 60 months</time_frame>
    <description>clinical complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local progression free survival</measure>
    <time_frame>every 6 months up to 60 months</time_frame>
    <description>time from the date of registration to the date of the first documented locoregional recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every 6 months up to 60 months</time_frame>
    <description>time from the date of registration to the date of death due to all causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastases free survival</measure>
    <time_frame>every 6 months up to 60 months</time_frame>
    <description>time from the date of registration to the date of first documented distant recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>before and after treatment up to 12 months</time_frame>
    <description>Utilization of the Patient Reported Outcomes- Common Toxicity Criteria for Adverse Events at pretreatment, 2 weeks, 4 weeks, 3, 6, and 12 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Anus Neoplasms</condition>
  <arm_group>
    <arm_group_label>Proton Therapy and Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard chemoradiation using 5-FU, Mitomycin, with pencil beam proton radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton therapy</intervention_name>
    <description>Primary target volume 50.4-54 CGE in 28-30 fractions; Nodal volumes 42-54 CGE in 28-30 fractions</description>
    <arm_group_label>Proton Therapy and Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29</description>
    <arm_group_label>Proton Therapy and Chemotherapy</arm_group_label>
    <other_name>5FU</other_name>
    <other_name>Mitomycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Karnofsky Performance Status &gt;70%

          -  Histologically documented squamous or basaloid carcinoma of the anal canal

          -  Stage T2-4 disease with any N category

        Exclusion Criteria:

        â€¢ Patients with a life expectancy of &lt; 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan Kharofa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UC Cancer Institute Clinical Trials Office</last_name>
    <phone>513-584-7698</phone>
    <email>kastla@ucmail.uc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Health</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UCCI Clinical Trials Office</last_name>
      <phone>513-584-7698</phone>
      <email>kastla@ucmail.uc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Jordan Kharofa</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Anal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

